ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1053

Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)
Abstract Number: 1054

Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Abstract Number: 1055

The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Abstract Number: 1056

High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
Abstract Number: 1057

Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
Abstract Number: 1058

Prevalence of Depression Associated with Rheumatologic Medications with Labeled Warnings: Real World Evidence from a Tertiary Care Center
Abstract Number: 1059

Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
Abstract Number: 1060

Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus
Abstract Number: 1061

Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Abstract Number: 1062

Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
Abstract Number: 1063

Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Abstract Number: 1064

Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Abstract Number: 1065

Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis
Abstract Number: 1066

Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 1067

Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].